Bronchial asthma is a heterogeneous disease whose definition and treatment are based on evidence of variable airway obstruction and airway inflammation. Despite the enormous increase in the amount of information on the pathogenesis of this disease, diagnosis is still an unresolved problem, as we still lack sensitive and specific biomarkers. On the other hand, at the turn of the 20th and 21st century, there was a rapid development of therapeutic modalities based on the principle of biological therapy. The first authorized drug matching these characteristics was omalizumab - a monoclonal antibody directed against immunoglobulin E (IgE). It has been used for the treatment of severe forms of bronchial asthma for more than 15 years, which is a sufficient time to acquire ways of its effective use and to assess whether the treatment with omalizumab has met our expectations. However, we continue to discover new and surprising facts about the effects of omalizumab treatment which leads to widening of therapeutic indications. In this work, a basic overview of the very complex role of the IgE molecule in the organism (with a special emphasis on allergic asthma) is discussed, and the most important practical and clinical consequences resulting from its modulation by targeted therapy with omalizumab are summarized.

Faculty of Medicine in Hradec Králové Charles University Prague Prague Czech Republic

Institute of Clinical Immunology and Allergology University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Boulet L-P, Bateman ED, Brusselle G, et al. Global strategy for asthma management and prevention (2019 Update), www.ginasthma.org (2019, accessed 27 June 2019).

Braman SS. The global burden of asthma. Chest 130: 4S–12S. PubMed

Hekking PPW, Wener RR, Amelink M, et al. (2015) The prevalence of severe refractory asthma. The Journal of Allergy and Clinical Immunology 135(4): 896–902. PubMed

Global Initiative for Asthma (GINA). Difficult-to-treat severe asthma in adolescent and adult patients GINA pocket guide for health professionals diagnosis and management, 2019, www.ginasthma.org

Chung KF, Wenzel SE, Brozek JL, et al. (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma task force report ERS/ATS guidelines on severe asthma Executive Summary. European Respiratory Journal 43: 343–373. PubMed

Fleming L, Heaney L. (2019) Severe asthma – Perspectives from adult and pediatric pulmonology. Frontiers in Pediatrics 7: 389. PubMed PMC

Montella S, Baraldi E, Cazzato S, et al. (2016) Severe asthma features in children: A case-control online survey. Italian Journal of Pediatrics 42: 9. PubMed PMC

Akdis A, Agache I, Asher MI, et al. (eds) Global Atlas of Asthma. EAACI, 2014, http://www.eaaci.org/resources/global-atlas-of-allergy.html

Tagaya E, Tamaoki J. (2007) Mechanisms of airway remodeling in asthma. Allergology International 56: 331–340. PubMed

Viswanathan RK, Busse WW. (2018) Biologic therapy and asthma. Seminars in Respiratory and Critical Care Medicine 39: 100–114. PubMed

Wenzel SE, Schwartz LB, Langmack EL, et al. (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. American Journal of Respiratory and Critical Care Medicine 160(3): 1001–1008. PubMed

Brusselle GG, Maes T, Bracke KR. (2013) Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine 19(8): 977–979. PubMed

Wenzel SE. (2012) Asthma phenotypes: The evolution from clinical to molecular approaches. Nature Medicine 18: 716–725. PubMed

Robinson D, Humbert M, Buhl R, et al. (2017) Revisiting Type 2-high and Type 2-low airway inflammation in asthma: Current knowledge and therapeutic implications. Clinical & Experimental Allergy 47(2): 161–175. PubMed

Godar M, Blanchetot C, de Haard H, et al. (2018) Personalized medicine with biologics for severe type 2 asthma: Current status and future prospects. MAbs 10(1): 34–45. PubMed PMC

Terl M, Sedlák V, Cap P, et al. (2017) Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. Allergy 72: 1279–1287. PubMed

Schleich FN, Manise M, Sele J, et al. (2013) Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulmonary Medicine 13: 1–8. PubMed PMC

Schleich F, Brusselle G, Louis R, et al. (2014) Heterogeneity of phenotypes in severe asthmatics. Respiratory Medicine 108(12): 1723–1732. PubMed

Katial RKK, Bensch GWW, Busse WWW, et al. (2017) Changing paradigms in the treatment of severe asthma: The role of biologic therapies. The Journal of Allergy and Clinical Immunology: In Practice 5(2S): S1–S14. PubMed

McGrath KW, Icitovic N, Boushey HA, et al. (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. American Journal of Respiratory and Critical Care Medicine 185: 612–619. PubMed PMC

Prausnitz C, Küstner H. (1921) Studien über Uberempfindlicht. Centralb Baketerial 1 Abt Orog 86: 160–169.

Johansson SGO, Stockholm S. (2016) The discovery of IgE. The Journal of Allergy and Clinical Immunology 137: 1671–1673. PubMed

Bennich HH, Ishizaka K, Johansson SGO, et al. (1968) Immunoglobulin E, A new class of human immunoglobulin. Bulletin of the World Health Organization 38: 151–152. PubMed PMC

Burrows B, Martinez FD, Halonen M, et al. (1989) Association of asthma with serum IgE levels and skin-test reactivity to allergens. The New England Journal of Medicine 320: 271–277. PubMed

Snapper CM, Finkelman FD, Paul WE. (1988) Regulation of IgG1 and IgE production by interleukin 4. Immunological Reviews 102: 51–75. PubMed

Bacharier Leonard D, Geha Raif S. (2000) Molecular mechanisms of IgE regulation. The Journal of Allergy and Clinical Immunology 105: 547–558. PubMed

Dustin ML. (2014) The immunological synapse. Cancer Immunology Research 2: 1023–1033. PubMed PMC

Stone KD, Prussin C, Metcalfe DD. (2010) IgE, mast cells, basophils, and eosinophils. The Journal of Allergy and Clinical Immunology 125: S73–S80. PubMed PMC

Ortega H, Chupp G, Bardin P, et al. (2014) The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal 44(1): 239–241. PubMed

Rabe KF, Nair P, Brusselle G, et al. (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. The New England Journal of Medicine 378: 2475–2485. PubMed

Corren J, Lemanske RF, Hanania NA, et al. (2011) Lebrikizumab treatment in adults with asthma. The New England Journal of Medicine 365: 1088–1098. PubMed

Gould HJ, Sutton BJ. (2008) IgE in allergy and asthma today. Nature Reviews Immunology 8(3): 205–217. PubMed

Karagiannis SN, Wang Q, East N, et al. (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. European Journal of Immunology 33(4): 1030–1040. PubMed

Garman SC, Kinet JP, Jardetzky TS. (1998) Crystal structure of the human high-affinity IgE receptor. Cell 95: 951–961. PubMed

Sutton BJ, Beavil RL, Beavil AJ. (2000) Inhibition of IgE-receptor interactions. British Medical Bulletin 56(4): 1004–1018. PubMed

Pelaia G, Canonica GW, Matucci A, et al. (2017) Targeted therapy in severe asthma today: Focus on immunoglobulin E. Drug Design, Development and Therapy 11: 1979–1987. PubMed PMC

Foster B, Metcalfe DD, Prussin C. (2003) Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: Correlation with serum IgE and allergic asthma. The Journal of Allergy and Clinical Immunology 112: 1132–1138. PubMed

Kikutani H, Yokota A, Uchibayashi N, et al. (1989) Structure and function of Fc epsilon receptor II (Fc epsilon RII/CD23): A point of contact between the effector phase of allergy and B cell differentiation. Ciba Foundation Symposium 147: 23–31, discussion; 31. PubMed

Palaniyandi S, Liu X, Periasamy S, et al. (2015) Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation. Mucosal Immunology 8(6): 1262–1274. PubMed PMC

Palaniyandi S, Tomei E, Li Z, et al. (2011) CD23-dependent transcytosis of IgE and immune complex across the polarized human respiratory epithelial cells. Journal of Immunology 186: 3484–3496. PubMed

Matucci A, Vultaggio A, Maggi E, et al. (2018) Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respiratory Research 19: 1–10. PubMed PMC

Stingl G, Maurer D. (1997) IgE-mediated allergen presentation via fc epsilon rl on antigen-presenting cells. International Archives of Allergy and Immunology 113: 24–29. PubMed

Maurer D, Ebner C, Reininger B, et al. (1995) The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. Journal of Immunology 154: 6285–6290. PubMed

Burton OT, Medina Tamayo J, Stranks AJ, et al. (2018) IgE promotes type 2 innate lymphoid cells in murine food allergy. Clinical & Experimental Allergy 48(3): 288–296. PubMed PMC

Colgan Isaiah L, Hankel Roy JJD, Carver LA. (2010) Rozhodující signální dráhy alergického zánětu v dýchacích cestách. Current Opinion in Allergy and Clinical Immunology 7: 42–47. PubMed

Vitte J. (2015) Human mast cell tryptase in biology and medicine. Molecular Immunology 63(1): 18–24. PubMed

Kambayashi T, Koretzky GA. (2007) Proximal signaling events in FcεRI-mediated mast cell activation. The Journal of Allergy and Clinical Immunology 119: 544–552. PubMed

Bradding P. (2007) Mast cell regulation of airway smooth muscle function in asthma. European Respiratory Journal 29(5): 827–830. PubMed

Redhu NS, Gounni AS. (2013) The high affinity IgE receptor (FcεRI) expression and function in airway smooth muscle. Pulmonary Pharmacology & Therapeutics 26(1): 86–94. PubMed

Belleau JT, Gandhi RK, McPherson HM, et al. (2005) Research upregulation of CD23 (FcεRII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clinical and Molecular Allergy 3: 6. PubMed PMC

Roth M, Zhong J, Zumkeller C, et al. (2013) The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS ONE 8(2): e56015. PubMed PMC

Roth M, Zhao F, Zhong J, et al. (2015) Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS ONE 10(9): e0136549. PubMed PMC

Fang L, Wang X, Sun Q, et al. (2019) IgE downregulates PTEN through microRNA-21-5p and stimulates airway smooth muscle cell remodeling. International Journal of Molecular Sciences 20: 1–20. PubMed PMC

Sihra BS, Kon OM, Grant JA, et al. (1997) Expression of high-affinity IgE receptors (FcεRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations. The Journal of Allergy and Clinical Immunology 99: 699–706. PubMed

Kim IS, Kim MJ, Kim DH, et al. (2013) Different anti-apoptotic effects of normal and asthmatic serum on normal eosinophil apoptosis depending on house dust mitespecific IgE. Molecular Biology Reports 40(10): 5875–5881. PubMed

Nagata K, Hirai H, Tanaka K, et al. (1999) CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Letters 459: 195–199. PubMed

Hirai H, Tanaka K, Yoshie O, et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. Journal of Experimental Medicine 193: 255–261. PubMed PMC

Pettipher R, Hansel TT, Armer R. (2007) Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nature Reviews Drug Discovery 6(4): 313–325. PubMed

Kupczyk M, Kuna P. (2017) Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: Current status and future perspectives. Drugs 77: 1281–1294. PubMed PMC

Domingo C, Palomares O, Sandham DA, et al. (2018) The prostaglandin D2 receptor 2 pathway in asthma: A key player in airway inflammation. Respiratory Research 19: 1–8. PubMed PMC

Marshall JS, Bell EB. (1985) Induction of an auto-anti-IgE response in rats. I. Effects on serum IgE concentrations. European Journal of Immunology 15(3): 272–277. PubMed

Corne J, Djukanovic R, Thomas L, et al. (1997) The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics. Journal of Clinical Investigation 99: 879–887. PubMed PMC

Busse W, Corren J, Lanier BQ, et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. The Journal of Allergy and Clinical Immunology 108(2): 184–190. PubMed

Solèr M, Matz J, Townley R, et al. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal 18(2): 254–261. PubMed

Buhl R, Solèr M, Matz J, et al. (2002) Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal 20(1): 73–78. PubMed

Hoshino M, Ohtawa J. (2012) Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 83(6): 520–528. PubMed

Lowe PJ, Renard D. (2011) Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. British Journal of Clinical Pharmacology 72(2): 306–320. PubMed PMC

Kroegel C, Foerster M, Lerche K, et al. (2015) Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations. European Respiratory Journal 46: PA2561.

Lin CH, Cheng SL. (2016) A review of omalizumab for the management of severe asthma. Drug Design, Development and Therapy 10: 2369–2378. PubMed PMC

Chan MA, Gigliotti NM, Dotson AL, et al. (2013) Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clinical and Translational Allergy 3: 1–8. PubMed PMC

Maggi L, Rossettini B, Montaini G, et al. (2018) Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. European Journal of Immunology 48(12): 2005–2014. PubMed

Teach SJ, Gill MA, Togias A, et al. (2015) Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. The Journal of Allergy and Clinical Immunology 136(6): 1476–1485. PubMed PMC

Labrador-Horrillo M, Ferrer M. (2015) Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design, Development and Therapy 9: 4909–4915. PubMed PMC

Gevaert P, Calus L, Van Zele T, et al. (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. The Journal of Allergy and Clinical Immunology 131(1): 110–116. PubMed

Bousquet J, Cabrera P, Berkman N, et al. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60(3): 302–308. PubMed

Brusselle G, Michils A, Louis R, et al. (2009) ‘Real-life’ effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respiratory Medicine 103(11): 1633–1642. PubMed

Braunstahl GJ, Chen CW, Maykut R, et al. (2013) The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine 107(8): 1141–1151. PubMed

Kirchnerová OR, Valena T, Novosad J, et al. (2019) Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic. Postepy Dermatol Alergol 36(1): 34–43. PubMed PMC

Bystroň J, Hutyrová B. (2016) Vyhodnocení účinnosti léčby anti-IgE monoklonální protilátkou nejen u těžkého alergického astmatu. Klinická Farmakologie A Farmacie 30: 14–18.

Deschildre A, Marguet C, Langlois C, et al. (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. European Respiratory Journal 46(3): 856–859. PubMed

Deschildre A, Marguet C, Salleron J, et al. (2013) Add-on omalizumab in children with severe allergic asthma: A 1-year real life survey. European Respiratory Journal 42: 1224–1233. PubMed

Licari A, Castagnoli R, Denicolo C, et al. (2017) Omalizumab in children with severe allergic asthma: The Italian real-life experience. Current Respiratory Medicine Reviews 13(1): 36–42. PubMed PMC

Humbert M, Taillé C, Mala L, et al. (2018) Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: The STELLAIR study. European Respiratory Journal 51(5): 1702523. PubMed PMC

Casale TB, Luskin AT, Busse W, et al. (2019) Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. The Journal of Allergy and Clinical Immunology: In Practice 7(1): 156–164.e1. PubMed

Bousquet J, Rabe K, Humbert M, et al. (2007) Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respiratory Medicine 101(7): 1483–1492. PubMed

Durrani SR, Viswanathan RK, Busse WW. (2011) What effect does asthma treatment have on airway remodeling? Current perspectives. The Journal of Allergy and Clinical Immunology 128(3): 439–448, quiz 449. PubMed

Rabe KF, Calhoun WJ, Smith N, et al. (2011) Can anti-IgE therapy prevent airway remodeling in allergic asthma. Allergy 66(9): 1142–1151. PubMed

Samitas K, Delimpoura V, Zervas E, et al. (2015) Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: Current knowledge and future perspectives. The European Respiratory Review 24(138): 594–601. PubMed PMC

Krčmová I, Novosad J, Malá E, et al. (2018) Small, prospective, observational, pilot study in severe asthmatic patients after omalizumab treatment discontinuation. Clinical Therapeutics 40: 1942–1953. PubMed

Nopp A, Johansson SGO, Adédoyin J, et al. (2010) After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 65(1): 56–60. PubMed

Nopp A, Johansson SGO, Ankerst J, et al. (2007) CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 62(10): 1175–1181. PubMed

Kupryś-Lipińska I, Kuna P. (2014) Loss of asthma control after cessation of omalizumab treatment: Real life data. Postepy Dermatol Alergol 31(1): 1–5. PubMed PMC

Molimard M, Mala L, Bourdeix I, et al. (2014) Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respiratory Medicine 108(4): 571–576. PubMed

Slavin RG, Ferioli C, Tannenbaum SJ, et al. (2009) Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. The Journal of Allergy and Clinical Immunology 123(1): 107–113. PubMed

Busse W, Trazskoma B, Omachi T, et al. (2014) Evaluating omalizumab persistency of response after long-term therapy (XPORT). European Respiratory Journal 44: 3485.

Ledford D, Busse WW, Trzaskoma B, et al. (2017) A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. The Journal of Allergy and Clinical Immunology 140(1): 162–169. PubMed